Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849461 | 1.00 | CHRNA7 (0.33) | CHRNA7CHRNB4CHRNA3HTR3ACHRNB2 | |
| SCHEMBL23267575 | 1.00 | CHRNA7 (0.33) | CHRNA7CHRNB4CHRNA3HTR3ACHRNB2 | |
| SCHEMBL16837171 | 0.89 | — | — | |
| SCHEMBL2143671 | 0.84 | — | — | |
| SCHEMBL21850190 | 0.84 | — | — | |
| SCHEMBL8255211 | 0.84 | — | — | |
| SCHEMBL9944703 | 0.84 | — | — | |
| SCHEMBL23265467 | 0.84 | — | — | |
| SCHEMBL16316909 | 0.84 | — | — | |
| SCHEMBL16882865 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086361-A1 | MOLECULAR GLUE DEGRADER COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024077023-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4328225-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4310084-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | Jinan University (CN) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023239629-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE CDK2 | Plexium, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2008106226-A2 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106225-A1 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106224-A1 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008094203-A2 | POLAR ESTER PRODRUGS OF HETEROCYCLIC HYBRID ANTIBACTERIAL COMPOUNDS AND SALTS THEREOF | MICROBIOTIX, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | disclosed |
| WO-2008053131-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
| US-20070219182-A1 | Keto Lactam Compounds and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-09-20 | — | — | US | disclosed |
| WO-2007007069-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006123121-A1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | CHRNA7 538/4885CHRNB4 472/4885CHRNA3 450/4885 |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | CHRNA7 4478/4885CHRNB4 4176/4885CHRNA3 4581/4885 |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | NPY1R, NPY2R, NPY5R | CHRNA7 749/4885CHRNB4 552/4885CHRNA3 588/4885 |
| US-20070219182-A1 | Keto Lactam Compounds and Use Thereof | OPRD1, DRD3, OPRK1 | CHRNA7 321/4885CHRNB4 522/4885CHRNA3 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.